Induction of Paclitaxel Resistance by the Kaposi's Sarcoma-Associated Herpesvirus Latent Protein LANA2 by Muñoz-Fontela, C. et al.
JOURNAL OF VIROLOGY, Feb. 2008, p. 1518–1525 Vol. 82, No. 3
0022-538X/08/$08.000 doi:10.1128/JVI.01704-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.
Induction of Paclitaxel Resistance by the Kaposi’s Sarcoma-Associated
Herpesvirus Latent Protein LANA2
C. Mun˜oz-Fontela,1,4† L. Marcos-Villar,1† F. Hernandez,2 P. Gallego,1,5 E. Rodriguez,1 J. Arroyo,1
S.-J. Gao,3 J. Avila,2 and C. Rivas1,5*
Departmento de Microbiologia II, Fac. Farmacia, Universidad Complutense de Madrid, Plaza Ramon y Cajal sn, Madrid 28040, Spain1;
Departmento de Biologia Molecular, Centro de Biologia Molecular Severo Ochoa, Universidad Autonoma Madrid, Madrid 28049,
Spain2; Department of Pediatrics and Children’s Cancer Research Institute, The University of Texas Health Science Center at
San Antonio, San Antonio, Texas 782293; Department of Oncological Sciences, Mount Sinai School of Medicine,
One Gustave L. Levy Place, Box 1130, New York, New York 100294; and Centro Nacional de Biotecnologia,
CSIC, Darwin 3, Campus Universidad Autonoma Madrid, Madrid 28049, Spain5
Received 6 August 2007/Accepted 12 November 2007
Kaposi’s sarcoma-associated herpesvirus (KSHV) is the causal agent of both KS and primary effusion
lymphoma (PEL). Although treatment with paclitaxel has significant antitumor activity in KS, drug resistance
represents a major obstacle for improving the overall response and survival of PEL patients. The transcrip-
tional pattern of KSHV is cell/tissue specific, as revealed by the fact that the viral latent protein LANA2 is
detected exclusively in B cells. This paper focuses on the mechanism of paclitaxel resistance observed in PEL
cells. Here we show that LANA2 protein modulates microtubule dynamics through its direct binding to
polymerized microtubules, preventing microtubule stabilization induced by paclitaxel. This is the first dem-
onstration of paclitaxel resistance induced by a viral protein and suggests a link between the expression of
LANA2 and the resistance of PEL cells to paclitaxel.
Kaposi’s sarcoma-associated herpesvirus (KSHV) is the
etiological agent of all forms of KS and lymphoproliferative
disorders, such as multicentric Castleman’s disease and pri-
mary effusion lymphoma (PEL). These disorders show dif-
ferent patterns of viral protein expression, probably due to
a cell-specific/tissue-specific control of KSHV gene expres-
sion that is likely to be relevant to understanding the patho-
genesis of KSHV-related diseases. In this sense, the protein
encoded by ORFK10.5, known as LANA2 or vIRF3, is de-
tected exclusively in B cells latently infected with the virus
(33). Although LANA2 was initially described as a nuclear
protein (33), subsequent studies have demonstrated it to be
a nucleocytoplasmic shuttling protein (24, 29). LANA2 has
been suggested to play an important role in KSHV-medi-
ated tumorigenesis, due to its ability to inhibit p53 and
PKR-dependent apoptosis (10, 33) or the virus-mediated
transcriptional activation of the alpha interferon promoter
(25). In addition to the differential KSHV gene expression,
KS and PEL show differential sensitivity to chemotherapy
treatment. PELs, unlike most non-Hodgkin’s lymphomas,
are relatively resistant to standard cytotoxic chemotherapy,
and virtually all PEL patients succumb to the disease, with a
median survival of approximately 60 days (20). In contrast,
KS has a good response to the chemotherapeutic agent
paclitaxel that received approval by the U.S. Food and Drug
Administration (FDA) for the treatment of KS (6, 27).
The taxane paclitaxel (Taxol) is a mitotic inhibitor used
commonly as a chemotherapeutic agent in the treatment of
breast and ovarian cancer or lymphomas. Paclitaxel binds in
vitro to the microtubule polymer, enhancing the polymeriza-
tion of tubulin (26, 31) and artificially stabilizing microtubules
(36, 42). Microtubules are dynamic structures involved in many
cellular processes, such as cellular division, proliferation, trans-
port, and maintenance of cell shape. Microtubule dynamics are
particularly critical during mitosis, as they are responsible for
the capture and alignment of chromosomes at metaphase and
the subsequent separation of the chromosomes into two
daughter cells at anaphase. The disruption of microtubule dy-
namics by taxanes leads first to mitotic arrest, resulting in a
sustained or transient cell cycle block and eventually to cell
death caused by an aberrant exit from mitosis (17, 23, 44, 48).
PEL cells are relatively resistant to paclitaxel treatment (1).
Several potential mechanisms can be proposed to account for
the paclitaxel resistance observed in PEL cells: altered metab-
olism of the drug, decreased sensitivity to death-inducing stim-
uli, alterations in microtubule dynamics and altered binding of
paclitaxel to the microtubule.
Here we show that the KSHV latent protein LANA2 has
associated microtubule-depolymerizing activity and inhibits
the binding of a fluorescent taxoid to its target, the microtu-
bule. These results (i) suggest that LANA2 is important in the
regulation of cytoskeleton organization and (ii) have implica-
tions for our understanding of the mechanisms of paclitaxel
resistance in PEL cells.
MATERIALS AND METHODS
Cell culture and transfection. The human breast cancer cell line MCF-7 and
the human embryonic kidney cell line HEK293 were grown in Dulbecco’s mod-
ified Eagle medium (DMEM) (Gibco BRL) supplemented with 10% fetal bovine
serum, penicillin (100 units/ml), streptomycin (100 g/ml), and 2 mM L-glu-
tamine. The NIH-3T3 cell line was grown in DMEM supplemented with antibi-
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otic, glutamine, and 10% calf serum. The BCP-1 PEL cell line (as well as the
KSHV-negative human B-cell lymphomas MHH-PREB-1 and Karpas-422) was
maintained in RPMI medium plus 20% fetal bovine serum supplemented with
antibiotics and glutamine. The 3T3-pcDNA and 3T3-LANA2 cell lines were
generated by stable transfection of NIH-3T3 cells with the empty vector pcDNA
or the LANA2 expression plasmid pcDNA-LANA2. Transfected cells were se-
lected by growth in the presence of 500 g ml1 G418. Stable pools (uncloned
mass culture) of transfected cells were maintained in DMEM supplemented with
10% calf serum and 500 g ml1 G418. Cells were transfected at 50 to 70%
confluence by using the cationic polymer transfection system (FuGENE; Roche)
or Lipofectamine (Invitrogen), according to the manufacturer’s instructions. In
some experiments, cells were treated 24 h after transfection with paclitaxel or
Flutax at concentrations between 10 nM and 10 M.
Plasmids, antibodies, and reagents. pcDNA-LANA2, EGFP-LANA2,
pcDNA-LANA2 (bp 1 to 430), pcDNA-LANA2 (bp 430 to 1066), pcDNA-
LANA2 (bp 1066 to 1321), and pcDNA-LANA2 (bp 1321 to 1706) plasmids were
described previously (30, 33). A bacmid containing the wild-type KSHV genome
(Bac36) and the green fluorescent protein (GFP) gene cassette was described
previously (49). Monoclonal anti-alpha-tubulin antibody was purchased from
AbD Serotec, anti-Foxo3a antibody was a gift from Eric W.-F. Lam (Imperial
College, London, United Kingdom), and anti-p53 antibody was kindly provided
by Manuel Serrano (CNIO, Madrid, Spain). Anti-actin antibody was obtained
from ICN. Anti-LANA2 antibody was purchased from Affinity BioReagents.
Antibody against alpha-tubulin acetylated on Lys 40 was obtained from Sigma.
Paclitaxel and nocodazole were purchased from Sigma. The fluorescent taxoid
Flutax was purchased from Molecular Probes.
Western blot analysis and immunofluorescence. Whole-cell lysates were pre-
pared by resuspending cell pellets in lysis buffer (50 mM Tris-HCl, 5 mM EDTA,
250 mM NaCl, 50 mM NaF, 0.1% Triton, 0.1 mM Na3VO4, and protease
inhibitors 1 mM phenylmethylsulfonyl fluoride and 1 g/ml aprotinin and leu-
peptin). The lysates were cleared by centrifugation for 15 min at 13,000  g at
4°C, and total protein extracts were determined. Protein lysates were resolved by
separation on sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels,
electroblotted, and incubated with the antibodies indicated. For immunofluores-
cence assays, cells were fixed in 2% paraformaldehyde-phosphate-buffered saline
(PBS) for 20 min at room temperature, followed by permeabilization in PBS-
0.5% Triton X-100 for 30 min at room temperature. After preblocking in 3%
bovine serum albumin-PBS for 30 min, cells were incubated for 60 min with the
correspondent antibodies and washed three times with PBS. Cells were then
incubated with secondary antibodies for 60 min at room temperature and washed
three times in PBS. Finally, cells were mounted with Mowiol containing or not
containing DAPI (4,6-diamidino-2-phenylindole; DAKO). Cell preparations
FIG. 1. LANA2 inhibits G2/M arrest induced by paclitaxel and prevents paclitaxel-induced microtubule polymerization. (a) MCF-7 cells
transfected with EGFP or EGFP-LANA2 were treated with 10 nM paclitaxel for 24 h, stained with propidium iodide for cell cycle analysis, and
subjected to flow cytometry. Numbers in lower panels show percentages of cells detected in each cell cycle phase in a representative experiment.
(b) Upregulation of p53 or Foxo3a levels after treatment of MCF-7 cells with low doses of paclitaxel (10 nM) for 24 h is not detected in cells
expressing LANA2. Cells were transfected and treated with paclitaxel as described above, and whole-cell lysates were subjected to sodium dodecyl
sulfate-polyacrylamide gel electrophoresis and probed for the proteins indicated. Actin serves as a loading control. The relative intensity of each
band was estimated densitometrically by normalizing the values from treated cells () to those from untreated cells () (relative density, 1) and
is displayed below each lane. (c) MCF-7 cells transfected with pcDNA or pcDNA-LANA2 were treated with 10 M paclitaxel for 24 h and
subsequently double-stained with anti-LANA2 and anti-tubulin antibodies and analyzed by fluorescence microscopy.
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were observed with a Nikon Eclipse TE2000-U microscope or with a Bio-Rad
laser scanning confocal microscope.
Cell cycle analysis. MCF-7 cells in 10-mm dishes were transfected with the
indicated plasmids and then incubated in the absence or presence of paclitaxel or
vinblastine 24 h after transfection. Cells were fixed and stained by using pro-
pidium iodine 48 h after transfection as described previously (30). The distribu-
tion of cells in the different phases of the cell cycle was determined by analytical
flow cytometry using a CyAn analyzer (DakoCytomation), and data were ana-
lyzed by using Summit software (DakoCytomation).
Live-cell Flutax binding studies. Cells were incubated with Flutax, and at the
indicated time, they were imaged using a Nikon Eclipse TE2000-U microscope.
In parallel, cells incubated with Flutax were washed in PBS and the fluorescent
taxoid content of intact cells, excluding propidium iodide, was determined by
flow cytometric analysis using a CyAn analyzer.
In vitro polymerization assay. In vitro transcription-translation of LANA2 was
carried out using the TNT quick coupled transcription/translation system (Pro-
mega). Phosphocellulose-purified tubulin was obtained from purified bovine
brain tubulin as described previously (46). In vitro tubulin assembly was per-
formed following the method of Vallee (43) in the presence or absence of
LANA2.
RESULTS
LANA2 inhibits both G2 arrest and microtubule polymer-
ization in response to paclitaxel. The treatment of some cell
lines with low doses of paclitaxel provokes cell cycle arrest in
G2/M due to the ability of paclitaxel to induce the stabilization
of microtubule and the disruption of the mitotic spindle (15,
17). The paclitaxel-sensitive breast cancer cell line MCF-7 was
transfected with enhanced GFP (EGFP)-LANA2 or the empty
vector pEGFP. Following treatment of the cells with 10 nM of
paclitaxel, a G2/M arrest was observed in the EGFP-expressing
cells, whereas no significant arrest was found in the EGFP-
FIG. 2. Expression of LANA2 inhibits the binding of Flutax. (a) NIH-3T3 cells stably expressing LANA2 were generated as described in
Materials and Methods. 3T3-pcDNA and pcDNA-LANA2 cells were then stained with the anti-LANA2 antibody (left panel) or subjected to
Western blot analysis with the same antibody (right panel). (b) 3T3-pcDNA and pcDNA-LANA2 cells were incubated in medium supplemented
with Flutax (10 M) for 60 min. The incorporation of Flutax was then analyzed in vivo by fluorescence microscopy (phase contrast image). A more
detailed image after the fixation and staining of the cells with DAPI cells is shown in the right panels. (c) Cells stably expressing LANA2 were
incubated with Flutax as described above and then analyzed for microtubule staining by flow cytometric analysis. (d) KSHV-negative (Karpas-422
and MHH-PREB-1) and KSHV-positive BCP-1 cell lines were incubated in medium supplemented with 500 nM Flutax, and after 16 h, cells were
analyzed for Flutax incorporation by flow cytometric analysis. FITC, fluorescein isothiocyanate.
1520 MUN˜OZ-FONTELA ET AL. J. VIROL.
LANA2-positive cells (Fig. 1a). Together with the G2/M arrest,
an increase in p53 and Foxo3a levels after paclitaxel treatment
has been reported previously (14, 35, 40). As shown in Fig. 1b,
the treatment of EGFP-transfected cells with 10 nM of pacli-
taxel induced an increase of p53 and Foxo3a protein levels that
was not observed after paclitaxel treatment of the EGFP-
LANA2-transfected cells. A high concentration of paclitaxel
increases polymer mass and also induces microtubule bundle
formation in interphase cells, a phenomenon that becomes a
hallmark of paclitaxel binding (37). When MCF-7 cells were
treated with concentrations of paclitaxel over 10 M, we ob-
served the formation of typical microtubule bundles as de-
scribed previously (Fig. 1c). However, bundle formation in
cells transfected with pcDNA-LANA2 was clearly reduced
(Fig. 1c).
LANA2 expression impairs the ability of the fluorescent
taxoid Flutax to bind microtubules. To directly characterize
the effect of the expression of LANA2 over paclitaxel action,
we employed a paclitaxel derivative conjugated with fluores-
cein isothiocyanate and Flutax and tested microtubule staining
in mouse NIH-3T3 fibroblasts. A derivative 3T3 cell line stably
expressing LANA2 was generated by the transfection of NIH-
3T3 cells with pcDNA-LANA2 and the selection by culture in
medium supplemented with G418. Cells resistant to G418
show the expression of LANA2, as demonstrated by Western
blot analysis or immunofluorescence with an anti-LANA2 an-
tibody (Fig. 2a). The incubation of cells in medium supple-
mented with Flutax (1 M) revealed stained microtubule cy-
toskeleton only in 3T3-pcDNA cells, not in 3T3-LANA2 cells
(Fig. 2b). The measurement of Flutax incorporation by flow
cytometric analysis revealed Flutax labeling in a population of
3T3-pcDNA cells at 60 min after drug exposure, whereas no
incorporation was found in the 3T3-LANA2 cells (Fig. 2c).
Although PEL cells have previously been demonstrated to be
resistant to paclitaxel treatment, the resistance of these cells to
bind to the taxoid component has not been reported. In order
to determine whether PEL cells are resistant to bind to Flutax,
KSHV-positive BCP-1 cells or the KSHV-negative B-cell lym-
phomas MHH-PREB-1 and Karpas-422 were incubated with
the fluorescent taxoid Flutax (1 M) for 16 h. After washing
cells with PBS, we determined the incorporation of Flutax by
flow cytometric analysis. More than 70% of the KSHV-nega-
tive B cells were positive for Flutax binding (Fig. 2d). However,
only 15% of the BCP-1 cells showed staining with the fluores-
cent compound (Fig. 2d), suggesting that the resistance of PEL
cells to paclitaxel is related to the inhibition of paclitaxel bind-
ing to these cells.
LANA2 binds to polymerized microtubules. To test whether
LANA2 can bind to microtubules, we performed an in vitro
microtubule cosedimentation assay with purified tubulin in the
presence of in vitro-translated LANA2 protein. After the po-
lymerization of tubulin, LANA2 was detected in the pellet
fraction associated with polymerized microtubules (Fig. 3a).
To determine whether there is a discrete region within the
primary structure of LANA2 that mediates microtubule bind-
ing, we tested the abilities of different LANA2 deletion con-
structs to associate with polymerized microtubules. Although
only the C terminus of LANA2 was detected exclusively in the
pellet fraction, two other LANA2 deletion constructs were
detected in the polymerized microtubule fraction, suggesting
that LANA2 binding is not restricted to a specific region (Fig.
3b). Finally, two-color fluorescence microscopy with the anti-
LANA2 antibody and a monoclonal antibody to alpha-tubulin
revealed that the LANA2 dots label microtubules in BCP-1
cells, indicating the colocalization of LANA2 and tubulin in
PEL cells (Fig. 3c).
LANA2 expression decreases microtubule stability. Acety-
lated tubulin is an indicator of stable microtubules; therefore,
we next examined the distribution of acetylated tubulin in the
LANA2-expressing cells. As shown in Fig. 4a, 3T3-LANA2
cells show diminished acetylated tubulin staining in compari-
son with that of the 3T3-pcDNA cells, suggesting that the
presence of LANA2 decreases microtubule stability. In addi-
tion, since vinblastine is known to destabilize microtubules (16,
19), cell cycle progression in the different cell lines following
exposure to vinblastine was also evaluated. As expected, con-
trol 3T3-pcDNA cells accumulated in the G2/M phase of the
FIG. 3. LANA2 protein interacts with tubulin. (a) In vitro-trans-
lated [35S]methionine LANA2 protein was incubated with purified
tubulin and subjected to an in vitro polymerization assay. Assembled
microtubules were separated from unpolymerized tubulin by centrifu-
gation. Shown are LANA2 and tubulin detected in supernatants (S
[unpolymerized tubulin]) and pellets (P [polymerized tubulin]). (b) In
vitro-translated [35S]methionine LANA2 deletion constructs were in-
cubated with purified tubulin and subjected to an in vitro polymeriza-
tion assay. Shown are LANA2 deletion constructs and tubulin in su-
pernatants (S) and pellets (P). (c) LANA2 colocalizes with tubulin in
KSHV-infected BCP-1 cells. Cytospins of BCP-1 cells were double-
stained with anti LANA2 and anti-alpha-tubulin antibody. The colo-
calization of both proteins is shown in yellow. Areas A, B, C, and D in
panel b correspond to areas designated for bp 1 to 1706.
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cell cycle after exposure to 8 nM vinblastine (Fig. 4b). Inter-
estingly, the treatment of 3T3-LANA2 cells with this depoly-
merizing agent resulted in a higher fraction of cells accumu-
lated in the G2/M phase and an accumulation of cells in the
hypodiploid region of the histograms. An increased sensitivity
to vinblastine by cells expressing LANA2 was also observed for
B cells. KSHV-negative MHH-PREB-1 cells show a mild de-
gree of G2/M arrest after incubation with 8 nM vinblastine for
24 h. However, a large fraction of hypodiploid cells was seen in
BCP-1 PEL cells following vinblastine exposure (Fig. 4b).
Coexpression of LANA2 with the KSHV latent proteins ex-
pressed in 293 cells prevents microtubule polymerization in
response to paclitaxel. In order to determine whether the
resistance of PEL cells to paclitaxel could be due to the ex-
pression of other KSHV latent genes, HEK293 cells were co-
transfected with the bacmid containing the KSHV genome and
GFP (Bac36) DNA, together with the empty vector pcDNA or
the pcDNA-LANA2 expression plasmid, and their responses
to paclitaxel were analyzed. As expected, HEK293 cells co-
transfected with Bac36 DNA and the empty vector pcDNA did
not show LANA2 expression, and only those cells cotrans-
fected with the pcDNA-LANA2 plasmid showed positive la-
beling for both Bac36 and LANA2 (Fig. 5). In addition, and as
shown in Fig. 5, aster-like microtubule changes induced by
paclitaxel treatment were detected only in cells cotransfected
with Bac36 DNA and pcDNA (not in cells expressing
LANA2), suggesting LANA2 as the main mediator of the
paclitaxel resistance observed in PEL cells.
DISCUSSION
Since its approval by the FDA in 1992 for the treatment of
ovarian cancer, the use of paclitaxel in cancer chemotherapy
has increased dramatically. The antiproliferative action of
paclitaxel relates to its abilities to bind tubulin, promote micro-
tubule assembly, and stabilize microtubules by bundle forma-
tion (22, 36, 37). These effects of the drug are correlated with
the arrest of cells in the G2/M phase of the cell cycle as well as
cellular toxicity (15, 34, 36). In this sense, those proteins that
regulate microtubule dynamics by interacting with tubulin
dimers or polymerized microtubules clearly have the potential
to modulate the sensitivity of a cell toward paclitaxel. The good
response to paclitaxel exhibited by KS resulted in the approval
of this drug by the FDA for its use in the treatment of this
disease (6, 27). However, there are no current therapies effec-
tive against PEL; it remains a fatal disease, with a median life
expectancy of approximately 2 months (20). The results in this
report demonstrate that the latent protein LANA2, expressed
exclusively in KSHV-infected B cells, was able to inhibit G2/M
cell cycle arrest and reduced bundle formation induced by the
chemotherapeutic agent paclitaxel in the MCF-7-sensitive cell
line. In addition, LANA2 impaired the ability of the fluores-
cent taxoid Flutax to bind and decorate microtubules. Since
Flutax competes with paclitaxel for the same microtubule bind-
ing site, these results suggest that LANA2 interferes with the
taxoid binding to microtubules. A predominant interaction of
FIG. 4. Expression of LANA2 decreases microtubule stability. (a) Expression of LANA2 diminishes acetylated tubulin staining. 3T3-pcDNA and
3T3-LANA2 cells were stained with anti-alpha-tubulin acetylated on Lys 40 antibody and visualized by fluorescence microscopy (upper panel) or
subjected to Western blot analysis with the indicated antibodies (lower panel). (b) Cell cycle progression in the presence of vinblastine of 3T3 and B cells
with or without expressing LANA2. 3T3-pcDNA, 3T3-LANA2, MHH-PREB-1, and BCP-1 cells were treated for 24 h with 8 nM vinblastine, and
subsequently, cell cycle analysis was carried out as described in Materials and Methods. Numbers in the lower panels show percentages of cells detected
in each cell cycle phase in a representative experiment.
FIG. 5. Cotransfection of pcDNA-LANA2 and Bac36 DNA decreases
the microtubule polymerization induced by paclitaxel. HEK293 cells were
transfected with Bac36 DNA, together with empty pcDNA or pcDNA-
LANA2, and then treated with 10 M paclitaxel for 24 h. Cells were then
fixed and stained with anti-LANA2 and anti-alpha-tubulin antibodies. Cells
expressing GFP, that is, those containing Bac36, and not expressing LANA2
show aster-like microtubule changes or altered tubulin structures induced by
paclitaxel treatment, while those positive for GFP (green), and thus carrying
Bac36, together with LANA2 (red), did not show the effects of paclitaxel.
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Flutax with sites at which tubulin is newly polymerized was
suggested (11). The results obtained after an in vitro tubulin
polymerization assay demonstrated that LANA2 was able to
interact with polymerized tubulin, thus reinforcing our hypoth-
esis.
Several mechanisms have been proposed to account for the
resistance observed in human tumors or cell lines to paclitaxel:
overexpression of the multidrug transporter P-glycoprotein
(13), altered metabolism of the drug, decreased sensitivity to
death-inducing stimuli (2), alterations in microtubule dynam-
ics, and altered binding of paclitaxel to its cellular target, the
microtubule (8, 9). Since the paclitaxel-binding site is present
only on polymerized tubulin, not on tubulin dimers (31), the
selection of a less stable polymer, that is, a polymer with in-
creased microtubule dynamics, could potentially offer a sur-
vival advantage for a tumor challenged with a microtubule-
stabilizing drug such as paclitaxel. According to Cabral and
coworkers, paclitaxel-resistant cell lines contain “hypostable”
microtubules in which the equilibrium between the dimer and
polymer is shifted toward the former (4, 5, 28). We wanted to
determine whether the binding of LANA2 to the tubulin might
alter the microtubule dynamics. It has been shown that a minor
population of microtubules is stabilized in cultured cells, and
they are enriched in acetylated and/or detyrosinated tubulin (3,
21, 32, 38, 39, 41, 45). In the present study, we have shown that
the level of acetylated tubulin was clearly reduced in the 3T3
cells expressing LANA2, suggesting that LANA2 expression is
responsible for a less stable polymer. These results are also in
agreement with the observation that in the paclitaxel-resistant
cell lines, the equilibrium between weakly and highly dynamic
microtubules has been shifted toward the latter (7, 12, 18, 47).
Moreover, since vinblastine is known to destabilize micro-
tubules (16, 19), LANA2 expression may result in increased
susceptibility to the mitotic effects of vinblastine. The stronger
perturbation in cell cycle progression observed in the LANA2-
expressing cells indicates that the expression of LANA2 results
in increased cell susceptibility to vinblastine.
The interference of LANA2 expression in KSHV-infected B
cells leads to a rapid induction of cell death (our unpublished
observations), thus precluding a direct demonstration of the
role of LANA2 in the paclitaxel resistance of PEL cells. How-
ever, in order to determine whether the resistance of PEL cells
to paclitaxel could be due to the expression of other KSHV
latent genes, HEK293 cells were cotransfected with the bacmid
containing the KSHV genome (Bac36). Cells transfected with
Bac36 DNA did not show any resistance to paclitaxel, pointing
to LANA2 as the main factor that mediates PEL resistance.
Together, these results demonstrate that LANA2 increases
cell resistance to paclitaxel by binding to polymerized tubulin
and by the modulation of microtubule dynamics. The identifi-
cation of LANA2 as a negative microtubule regulator sheds
new light on its role in PEL resistance to paclitaxel.
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